HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Zydus receives approvals from USFDA for Albendazole Tablets
Dec-15-2018

Zydus Cadila has received the final approval from the USFDA to market Albendazole Tablets USP (US RLD - ALBENZA tablets), 200 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad in the state of Gujarat. This medication is used to treat certain tapeworm infections (such as neurocysticercosis and hydatid disease).

The company also received a tentative approval for Pregabalin Capsules (US RLD - Lyrica) in the strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad in the state of Gujarat. Pregabalin is used to help control certain kinds of seizures, painful nerve diseases and fibromyalgia.

The group now has 239 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

  RELATED NEWS >>